Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512386 | 1.00 | S1PR1 (0.57) | S1PR1S1PR3S1PR5HDAC1 | |
| SCHEMBL3509474 | 0.97 | S1PR1 (0.61) | S1PR1S1PR3S1PR5 | |
| SCHEMBL385523 | 0.97 | S1PR1 (0.61) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3511507 | 0.91 | S1PR1 (0.55) | S1PR1S1PR3S1PR5HDAC1 | |
| SCHEMBL3512788 | 0.91 | S1PR1 (0.55) | S1PR1S1PR3S1PR5HDAC1 | |
| SCHEMBL3510888 | 0.90 | S1PR1 (0.69) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3511310 | 0.90 | S1PR1 (0.69) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3512798 | 0.88 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1453222 | 0.88 | S1PR1 (0.58) | S1PR1S1PR3S1PR5HDAC1 | |
| SCHEMBL3508312 | 0.88 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | PPARG, PPARA, PPARD | S1PR1 282/4885S1PR3 281/4885S1PR5 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.